Riskpilot← Back to searchSign inGet full accessCytiva BioProcess R&D AB
ABActiveOrg 5567077366Björkgatan 30Leasing of intellectual property and similar products, except copyrighted works · NACE 7740Est. 20060 employees
Revenue 2024
SEK 13,1B
+2% vs 2023
EBITDA margin
95.6%
+2% vs 2023
Equity ratio
50.0%
Financial strength
Net profit 2024
SEK -1,8B
-644% vs 2023
| Revenue | SEK 13,1B | +2% |
| EBITDA | SEK 12,5B | +2% |
| Net profit | SEK -1,8B | -644% |
| Total assets | SEK 24,9B | -33% |
| Equity | SEK 12,4B | -45% |
| Employees | 0 | — |
Legal name
Cytiva BioProcess R&D AB
Org number
5567077366
Legal form
Aktiebolag
NACE code
7740 · Leasing of intellectual property and similar products, except copyrighted works
Founded
12 juli 2006
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är att utveckla, kommersialisera och utlicensiera immateriella rättigheter och know-how avseende kemiska produkter och apparater, främs inom biokemisk separationsteknik, molekylärbiologi och cellbiologi, ävensom, att driva annan därmed förenlig verksamhet.
Address
Björkgatan 30
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 9 958 028 | 14 786 287 | 17 011 724 | 12 787 611 | 13 084 681 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 9 802 006 | 14 474 639 | 16 485 575 | 12 264 229 | 12 511 744 |
| Depreciation & amort. | −6 577 069 | −6 577 069 | −6 577 069 | −6 577 194 | −6 624 266 |
| EBIT | 3 224 937 | 7 897 570 | 9 908 506 | 5 687 035 | 5 887 478 |
| Net financials | −11 944 | −13 201 | −6 560 | 334 715 | −1 819 084 |
| Profit before tax | 6 419 869 | −1 | 0 | 333 691 | −1 819 062 |
| Tax | −0 | −0 | −1 351 | 405 | −0 |
| Net profit | 6 419 869 | −1 | −1 351 | 334 096 | −1 819 062 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 41 468 776 | 26 555 022 | 35 410 790 | 36 946 293 | 24 871 411 |
| Equity | 26 496 422 | 1 996 421 | 7 995 070 | 22 706 214 | 12 442 310 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 868 956 | 13 444 433 | 22 878 621 | 14 240 079 | 12 429 100 |
| Total debt | 868 956 | 13 444 433 | 22 878 621 | 14 240 079 | 12 429 100 |
EBITDA margin
95.6%
This company
15.8%
Market median
+505% vs market
20202024
Equity ratio
50.0%
This company
38.2%
Market median
+31% vs market
20202024
Return on equity
-14.6%
This company
18.4%
Market median
-179% vs market
20202024
Net profit margin
-13.9%
This company
8.1%
Market median
-272% vs market
20202024
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20202024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JM Chief Auditor | Chief Auditor | 2020 |
| Former (1) | ||
BA Chief Auditor | Chief Auditor | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2020 | |
| Chairman | 2020 | |
| Board of Directors | 2025 | |
| Former (3) | ||
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2022 – 2023 | |
| Board of Directors | 2020 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PALL NETHERLANDS B.V
Cytiva BioProcess R&D AB Board members of Cytiva BioProcess R&D AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jonatan Mattias Hansson | Chief Auditor | 0 companies |
| Bjarne Alfred Andreassen | Chief Auditor | 0 companies |
| Marie Ester Kristina Wulff | Board of Directors | 0 companies |
| Christel Fenge | Board of Directors | 0 companies |
| Manuel Valiente Stegeman | Board of Directors | 0 companies |
| Sofie Christina Stille | Board of Directors | 0 companies |
| Ann-Christine M Hult Löfgren | Chairman | 0 companies |
| John Daicic | Board of Directors | 0 companies |